Santa Monica-based prescription medication discount provider GoodRx Holdings Inc. wants its customers and other medication ...

The National Community Pharmacists Association has joined a class action lawsuit against GoodRx, as well as CVS Caremark, ...

We recently compiled a list of the 10 Best Affordable Stocks Under $5 to Buy Now. In this article, we are going to take a ...

NEW YORK, Jan. 14 (Xinhua) -- The largest pharmacy-benefit managers (PBMs) hiked the prices of certain drugs dispensed through their own pharmacies, according to a new report by the Federal Trade ...

US FTC Finds Major Pharmacy Benefit Managers Inflated Drug Prices for $7.3 Billion Gain By Ahmed Aboulenein and Amina Niasse WASHINGTON (Reuters) -The nation's three largest pharmacy benefit ...

Pharmacy benefit managers, or PBMs, act as middlemen within the pharmaceutical industry. They negotiate rebates from wholesale prices with drugmakers, before passing some of the discount on to ...

WASHINGTON (Reuters) -The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their ...

WASHINGTON (Reuters) -The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their ...

BofA lowered the firm’s price target ... outlook for GoodRx’s core prescription business is unclear heading into 2025, as pharmacies are pushing back more aggressively on pharmacy benefit ...

Likewise, if a pharmacy provides a doctor to write a prescription for you (often without an exam), this practice is unsafe and illegal. Watch out for unusual prices. If you are paying for your ...

GDRX stock opened at $4.55 on Wednesday. The stock has a 50-day moving average price of $4.72 and a two-hundred day moving average price of $6.57. GoodRx has a 1 year low of $4.09 and a 1 year ...

Citi analyst Daniel Grosslight lowered the firm’s price target on GoodRx (GDRX) to $6.25 from $7 and keeps a Buy rating on the shares as part of a 2025 outcook for the health technology and ...